johnson & johnson news - Search News

Intra-Cellular, Johnson & Johnson

The Wall Street Journal on MSN · 25m

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal

Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.

Barron's on MSN · 46m

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular

Johnson & Johnson has entered an agreement to acquire all outstanding shares of Intra-Cellular Therapies, in a multibillion-dollar bet on mental health therapies. Johnson & Johnson will pay $132 per share in cash for a total equity value of $14.

FiercePharma · 2h

JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B

At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that develops and markets products for the central nervous system.

2d

Johnson & Johnson Could Serve As High-Yield Bond Alternative

Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

2don MSN

Johnson & Johnson stock outperforms competitors despite losses on the day

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Johnson & Johnson MedTech halts Varipulse PFA cases due to stroke reports

Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...

2d

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

5d

Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results